Dougherty & Co initiated coverage on shares of Medidata Solutions, Inc. (NASDAQ:MDSO) in a research note issued to investors on Thursday, November 2nd, Marketbeat.com reports. The firm issued a neutral rating on the stock.
A number of other equities analysts also recently issued reports on MDSO. Zacks Investment Research downgraded shares of Medidata Solutions from a hold rating to a sell rating in a research note on Thursday, November 2nd. Jefferies Group LLC reaffirmed a hold rating and set a $78.00 target price on shares of Medidata Solutions in a research note on Tuesday, August 22nd. Needham & Company LLC reaffirmed a buy rating and set a $90.00 target price (up previously from $75.00) on shares of Medidata Solutions in a research note on Friday, July 21st. Royal Bank Of Canada assumed coverage on shares of Medidata Solutions in a research note on Tuesday, September 19th. They set a sector perform rating and a $82.00 target price for the company. Finally, Citigroup Inc. reiterated a buy rating and set a $94.00 price target (up previously from $77.00) on shares of Medidata Solutions in a report on Monday, July 10th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $84.25.
Medidata Solutions (MDSO) opened at $65.69 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. Medidata Solutions has a 1 year low of $47.77 and a 1 year high of $85.92. The stock has a market cap of $3,840.30, a price-to-earnings ratio of 79.14, a P/E/G ratio of 3.95 and a beta of 1.78.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. The business had revenue of $140.08 million during the quarter, compared to analyst estimates of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 earnings per share. analysts predict that Medidata Solutions will post 0.77 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://ledgergazette.com/2017/11/13/medidata-solutions-inc-mdso-now-covered-by-dougherty-co.html.
In other Medidata Solutions news, Director Robert Taylor sold 5,000 shares of Medidata Solutions stock in a transaction on Monday, November 6th. The shares were sold at an average price of $71.39, for a total value of $356,950.00. Following the completion of the transaction, the director now directly owns 49,372 shares of the company’s stock, valued at approximately $3,524,667.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael I. Otner sold 10,000 shares of Medidata Solutions stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total transaction of $708,800.00. Following the completion of the transaction, the executive vice president now directly owns 80,674 shares of the company’s stock, valued at $5,718,173.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 220,000 shares of company stock worth $15,190,400. 5.80% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Fortaleza Asset Management Inc. purchased a new position in shares of Medidata Solutions during the 3rd quarter worth about $155,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Medidata Solutions by 10.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock worth $171,000 after purchasing an additional 208 shares during the period. Parametrica Management Ltd purchased a new position in shares of Medidata Solutions during the 2nd quarter worth about $216,000. Cubist Systematic Strategies LLC purchased a new position in shares of Medidata Solutions during the 2nd quarter worth about $227,000. Finally, ETF Managers Group LLC purchased a new position in shares of Medidata Solutions during the 2nd quarter worth about $233,000. 97.52% of the stock is owned by hedge funds and other institutional investors.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.